Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases.
$34.39+5.72%
报价 2026-11-06
市值
$2.4B
EV
–
PE (TTM)
–
预期 PE
–
52 周区间距高点 -11.5%
$22.63$38.86
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Biotechnology| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| PHVSPharvaris N.V. | $2.4B | +5.7% | – | 0% | – | – | – | |
| RCUSArcus Biosciences, Inc. | $2.59B | +3.3% | -70.3% | 97% | – | – | – | |
| PVLAPalvella Therapeutics, Inc. | $2.53B | +12.2% | – | 0% | – | – | – | |
| MBXMBX Biosciences, Inc. Common Stock | $2.47B | +6.0% | – | 0% | – | – | – | |
| CLDXCelldex Therapeutics, Inc. | $2.35B | +5.7% | -11.1% | 100% | – | – | – | |
| COAGHemab Therapeutics Holdings, Inc. Common Stock | $2.29B | +7.6% | – | 0% | – | – | – | |
| SEPNSepterna, Inc. | $2.28B | +3.2% | +94.3% | 99.4% | – | – | 16.4x | |
| NAMSNewAmsterdam Pharma Company N.V. | $2.26B | +0.1% | – | 99.7% | – | – | – | |
| IMNMImmunome, Inc. | $2.21B | +4.5% | -67.5% | -1,161.9% | – | – | – | |
| 同行中位数 | – | – | -39.3% | 48.5% | – | – | 16.4x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
报告货币 EUR（非美元）暂无季度数据（首次研究运行后填充）。